Quinoxaline-Based Anti-Schistosomal Compounds Have Potent Anti-Malarial Activity

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• * Plasmodium and Schistosoma cause over 200 million infections annually, disproportionately affecting low- and middle-income countries.
• * Drug resistance in Plasmodium and lack of targets for Schistosoma necessitate novel therapeutic strategies.

Conclusions:

• * Quinoxaline derivatives are promising candidates for treating both malaria and schistosomiasis.
• * PfQRP1 and PfATP2 are identified as potential drug targets in Plasmodium falciparum.
• * Understanding resistance mechanisms is crucial for developing effective anti-parasitic drugs.